Understanding Ependymomas of the 4th Ventricle

Ependymomas are rare, slow-growing tumors that arise from ependymal cells lining the ventricular system of the brain and the central canal of the spinal cord. When located in the 4th ventricle, they present unique diagnostic and surgical challenges due to the proximity of critical brainstem structures and cerebellar pathways.

Key Features and Pathology

These tumors are most common in children and young adults, but can occur at any age. Histologically, ependymomas are characterized by perivascular pseudorosettes and true rosettes. The World Health Organization (WHO) classifies them into Grade I (subependymoma, myxopapillary), Grade II (classic ependymoma), and Grade III (anaplastic ependymoma). The genetic landscape, including mutations in NF2 and RELA fusion genes, is increasingly important for prognosis and targeted therapy.

Clinical Presentation and Symptoms

Because the 4th ventricle is a narrow passage connecting the aqueduct of Sylvius to the central canal, even small ependymomas can obstruct cerebrospinal fluid (CSF) flow, leading to hydrocephalus. Common symptoms include:

• Headaches (often worse in the morning)
• Nausea and vomiting
• Ataxia and balance difficulties
• Diplopia (double vision)
• Papilledema
• Cranial nerve deficits (especially VI and VII)

Diagnosis and Imaging

MRI with gadolinium contrast is the gold standard for diagnosis. On T1-weighted images, ependymomas appear hypointense to isointense, while on T2-weighted sequences they are hyperintense. Heterogeneous enhancement is common, and often the tumor extends through the foramina of Luschka and Magendie (the "plastic" or "toothpaste" appearance). CT scans may show calcifications and cystic components.

Treatment and Prognosis

The primary treatment is surgical resection with the goal of gross total resection (GTR). The extent of resection is the strongest predictor of outcome. Postoperative radiation therapy is often employed, especially for anaplastic or subtotally resected tumors. Chemotherapy is reserved for young children (to delay radiation) or recurrent disease. The prognosis is related to age, tumor grade, and genetic markers: RELA fusion-positive supratentorial ependymomas may have a worse outcome, while posterior fossa group A (PFA) ependymomas are particularly aggressive in infants.

Complications and Surgical Risks

Surgery in the 4th ventricle carries risks of damage to the brainstem and cranial nerve nuclei. Common complications include cerebellar mutism (especially in children), lower cranial nerve palsies, and aseptic meningitis. Preoperative shunting for hydrocephalus is sometimes required.

Future Directions

Current research focuses on molecular subtyping to guide targeted therapies. Immunotherapy and novel agents targeting the Hedgehog and WNT pathways are under investigation. The role of stem cells in tumor recurrence is also an active area of study.